<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340003</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">971</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090971</ELocationID><Abstract><AbstractText>Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. Online surveys were sent via AusVaxSafety, Australia's active vaccine safety surveillance system, three and eight days after vaccination. A total of 131,775 day 3 surveys were sent, with a response rate of 38.5% (<i>N</i> = 50,721). A total of 43,875 day 8 surveys matched with day 3 survey responses were sent, with a response rate of 71.5% (<i>N</i> = 31,355). Half (50.7%) of respondents reported any adverse event following immunisation (AEFI) in the 0-3 days after vaccination and 24.6% reported any AEFI 4-7 days after vaccination. Fatigue, local pain, headache, and myalgia were the most frequently reported symptoms for both vaccines in both periods. After adjusting for respondent characteristics, vaccination clinic type, jurisdiction, and medical conditions, the odds for reporting AEFI increased with age from 16-19 years to highest odds at 30-39 years, after which it declined. Females had greater odd of reporting AEFI than males across most age groups, vaccine types, and doses. Respondents with a history of anaphylaxis had greater odds of reporting any AEFI (adjusted OR range: 1.50-2.86). A total of 3.1% of respondents reported seeking medical review 0-3 days after vaccination. This study affirms the short-term safety of Spikevax and Nuvaxovid COVID-19 vaccine priming doses in a large sample in Australia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Renee</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9849-551X</Identifier><AffiliationInfo><Affiliation>Population Health, Hunter New England Local Health District, Wallsend, NSW 2287, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tay</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dymock</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4881-2860</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0066-2218</Identifier><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Children's Hospital at Westmead, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glover</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Laura K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuanfei Anny</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cashman</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7183-1360</Identifier><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leeb</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Child Health Research, University of Western Australia, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Illawarra Medical Centre, Ballajura, Perth, WA 6066, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Child Health Research, University of Western Australia, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snelling</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4670-0638</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Children's Hospital at Westmead, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macartney</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Children's Hospital at Westmead, Westmead, Sydney, NSW 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Health/20-21/PH20/17578</GrantID><Agency>Australian Government Department of Health and Aged Care</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Moderna</Keyword><Keyword MajorTopicYN="N">Novavax</Keyword><Keyword MajorTopicYN="N">active surveillance</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340003</ArticleId><ArticleId IdType="pmc">PMC11435866</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090971</ArticleId><ArticleId IdType="pii">vaccines12090971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deng L., Glover C., Dymock M., Pillsbury A., Marsh J.A., Quinn H.E., Leeb A., Cashman P., Snelling T.L., Wood N. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February–August 2021. Med. J. Aust. 2022;217:195–202. doi: 10.5694/mja2.51619.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.51619</ArticleId><ArticleId IdType="pmc">PMC9350119</ArticleId><ArticleId IdType="pubmed">35781813</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Department of Health and Aged Care  COVID-19 Vaccines Regulatory Status.  [(accessed on 20 October 2023)]; Available online:  https://www.tga.gov.au/products/covid-19/covid-19-vaccines/covid-19-vaccines-regulatory-status.</Citation></Reference><Reference><Citation>Australian Department of Health and Aged Care  Vaxzevria (AstraZeneca) Vaccine and Thrombosis with Thrombocytopenia (TTS)  [(accessed on 9 February 2024)]; Available online:  https://www.health.gov.au/our-work/covid-19-vaccines/advice-for-providers/clinical-guidance/tts.</Citation></Reference><Reference><Citation>Australian Department of Health and Aged Care  Guidance on Myocarditis and Pericarditis after COVID-19 Vaccines.  [(accessed on 20 June 2024)]; Available online:  https://www.health.gov.au/sites/default/files/2024-01/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-covid-19-vaccines.pdf.</Citation></Reference><Reference><Citation>Rittle C., Walter L. COVID-19 Vaccines and mRNA Technology: Not as New as Many Believe. Online J. Issues Nurs. 2022;27:1–11. doi: 10.3912/OJIN.Vol27No02PPT752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3912/OJIN.Vol27No02PPT752</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter N., King C., Deng L., Wood N., Quinn H. Australian health-care providers awareness of and practices related to vaccine safety surveillance. Public Health Res. Pract. 2024. submitted for publication .</Citation></Reference><Reference><Citation>Pillsbury A., Cashman P., Leeb A., Regan A., Westphal D., Snelling T., Blyth C., Crawford N., Wood N., Macartney K. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Eurosurveillance. 2015;20:30050. doi: 10.2807/1560-7917.ES.2015.20.43.30050.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2015.20.43.30050</ArticleId><ArticleId IdType="pubmed">26536867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacoby P., Glover C., Damon C., Fathima P., Pillsbury A., Durrheim D., Gold M.S., Leeb A., Snelling T. Timeliness of signal detection for adverse events following influenza vaccination in young children: A simulation case study. BMJ Open. 2020;10:e031851. doi: 10.1136/bmjopen-2019-031851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-031851</ArticleId><ArticleId IdType="pmc">PMC7050305</ArticleId><ArticleId IdType="pubmed">32122906</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Department of Health and Aged Care  COVID-19 Vaccine Safety Monitoring and Reporting. Information on How the TGA Monitors COVID-19 Vaccine Safety, Reporting Suspected Side Effects and COVID-19 Safety Updates.  [(accessed on 9 February 2024)]; Available online:  https://www.tga.gov.au/products/covid-19/covid-19-vaccines/covid-19-vaccine-safety-monitoring-and-reporting.</Citation></Reference><Reference><Citation>Chapin-Bardales J., Gee J., Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325:2201–2202. doi: 10.1001/jama.2021.5374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5374</ArticleId><ArticleId IdType="pubmed">33818592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kant A., Jansen J., van Balveren L., van Hunsel F. Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands. Drug Saf. 2022;45:319–331. doi: 10.1007/s40264-022-01151-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01151-w</ArticleId><ArticleId IdType="pmc">PMC8936041</ArticleId><ArticleId IdType="pubmed">35314943</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra-Estévez D., Palomo-Palomo C., Parrado-González A., Estaire-Gutiérrez J., Reyes-Malia M., Romero-Alonso M.M. Self-reported adverse events within the seven days following the Spikevax®(Moderna) vaccination. Farm. Hosp. 2022;46:301–307.</Citation><ArticleIdList><ArticleId IdType="pubmed">36183231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Ko M., Heo Y., Lee Y.-K., Kwon Y., Choi S.-K., Bahng E. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over. Vaccine. 2023;41:5066–5071. doi: 10.1016/j.vaccine.2023.06.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.06.077</ArticleId><ArticleId IdType="pmc">PMC10293897</ArticleId><ArticleId IdType="pubmed">37422379</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter S.M., Li D., Trentino K., Nissen L., Lee K., Orlemann K., Peters I., Murray K., Leeb A., Deng L. Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations. Vaccines. 2022;10:2017. doi: 10.3390/vaccines10122017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122017</ArticleId><ArticleId IdType="pmc">PMC9786585</ArticleId><ArticleId IdType="pubmed">36560426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaxtracker  About Vaxtracker.  [(accessed on 2 July 2023)].  Available online:  https://www.vaxtracker.net/About/Index.</Citation></Reference><Reference><Citation>SmartVax  About SmartVax.  [(accessed on 2 July 2023)].  Available online:  https://www.smartvax.com.au/about-smartvax-vaccine-surveillance-system/</Citation></Reference><Reference><Citation>Department of Health (Victoria)  Victorian COVID-19 Vaccination Program. COVID-19 Vaccination Management System Operating Model and Process Considerations for Health Services. 19 February 2021.  [(accessed on 5 July 2023)].  Available online:  https://coronavirus.wh.org.au/wp-content/uploads/2021/03/C-CVMS-operating-model-and-process-considerations-for-health-services-19.02.2021.pdf.</Citation></Reference><Reference><Citation>Queensland Health  Vaccination Readiness Assurance Plan 3.0.  [(accessed on 5 July 2023)]; Available online:  https://www.health.qld.gov.au/__data/assets/pdf_file/0022/1130278/covid-19-vaccination-readiness-plan-vrap.pdf.</Citation></Reference><Reference><Citation>R Core Team  R: A Language and Environment for Statistical Computing.  [(accessed on 30 July 2023)].  Available online:  https://www.r-project.org/</Citation></Reference><Reference><Citation>MedDRA MSSO . Introductory Guide to MedDRA Version 26.0. MedDRA Maintenance and Support Services Organization; McLean, VA, USA: 2023.</Citation></Reference><Reference><Citation>Gelman A., Carlin J.B., Stern H.S., Dunson D.B., Veharti A., Rubin D.B. Baysian Data Analysis. 3rd ed. Chapman and Hall/CRC Press; Boca Raton, FL, USA: 2013.</Citation></Reference><Reference><Citation>McElreath R. Statistical Rethinking: A Bayesian Course with Examples in R and STAN. 2nd ed. Chapman &amp; Hall/CRC Press; Boca Raton, FL, USA: 2020.</Citation></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N. Engl. J. Med. 2021;385:1172–1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Bureau of Statistics  Estimates of Aboriginal and Torres Strait Islander Australians.  [(accessed on 2 April 2024)]; Available online:  https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-aboriginal-and-torres-strait-islander-australians/latest-release.</Citation></Reference><Reference><Citation>Australian Department of Health  COVID-19 Vaccine Roll-Out. 20 January 2022.  [(accessed on 23 May 2023)]; Available online:  https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-rollout-update-20-january-2022.pdf.</Citation></Reference><Reference><Citation>Attwoll J. How Many People Were ‘Waiting for Novavax?’.  [(accessed on 27 May 2024)].  Available online:  https://www1.racgp.org.au/newsgp/clinical/how-many-people-were-waiting-for-novavax.</Citation></Reference><Reference><Citation>O’Neill G.K., Taylor J., Kok J., Dwyer D.E., Dilcher M., Hua H., Levy A., Smith D., Minney-Smith C.A., Wood T. Circulation of influenza and other respiratory viruses during the COVID-19 pandemic in Australia and New Zealand, 2020–2021. West. Pac. Surveill. Response J. WPSAR. 2023;14:1. doi: 10.5365/wpsar.2023.14.3.948.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2023.14.3.948</ArticleId><ArticleId IdType="pmc">PMC10630701</ArticleId><ArticleId IdType="pubmed">37946717</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>